Latanoprost Market By Type (Branded Drug, Generic Drug) , By Indication (Open Angle Glaucoma, Ocular Hypertension) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The latanoprost market was valued at $1.3 billion in 2023, and is projected to reach $1.6 billion by 2033, growing at a CAGR of 2.1% from 2024 to 2033.
Latanoprost is a medication primarily used in the treatment of glaucoma and ocular hypertension. It is classified as a prostaglandin analog, and works by increasing the outflow of fluid from the eye, which helps to lower intraocular pressure. Latanoprost is often prescribed to reduce the risk of damage to the optic nerve, a common complication of glaucoma, which can lead to vision loss if left untreated.
Increase in number of individuals diagnosed with glaucoma and ocular hypertension globally drives the growth of the latanoprost market. As these conditions are leading causes of vision loss, their rising prevalence fuels the market growth. As per a 2023 study published by the National Institutes of Health, approximately 70 million individuals are suffering from glaucoma worldwide. In addition, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that as the global population ages, the incidence of age-related eye conditions is expected to rise. Older adults are more likely to experience increased intraocular pressure, which directly boosts the demand for medications like latanoprost. Moreover, rise in awareness about eye health and the importance of regular eye check-ups among both patients and healthcare providers contributes to earlier detection and treatment of glaucoma, leading to higher latanoprost market adoption. Furthermore, the availability of generic latanoprost products at a lower cost has expanded the treatment options for patients, driving the growth of the market by increasing affordability and access to the drug. However, side effects and adverse reactions associated with latanoprost such as eye irritation, changes in eye color, and potential systemic effects hamper the market growth. In addition, availability of alternative medications for glaucoma, such as other prostaglandin analogs (e.g., travoprost and bimatoprost) or non-prostaglandin therapies, significantly restrains the market growth. On the contrary, ongoing advancements in ophthalmic drug formulations and delivery systems improve the effectiveness of treatments like latanoprost, making it a more attractive option for patients. Innovations, such as sustained-release formulations, enhance patient compliance and are expected to offer lucrative opportunities for the expansion of the global market during the forecast period.
The global latanoprost market size is segmented into type, indication, distribution channel, and region. On the basis type, the market is bifurcated into branded drug and generic drug. Depending on indication, it is segregated into open angle glaucoma and ocular hypertension. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By type, the branded drug segment is expected to dominate the market from 2024 to 2033.
On the basis of indication, the open-angle glaucoma segment is anticipated to exhibit highest growth during the forecast period.
Depending on distribution channel, the retail pharmacies segment is projected to grow at a notable pace throughout the forecast period.
Region wise, North America is likely to emerge as the most lucrative market for latanoprost in the coming years.
Competition Analysis
Competitive analysis and profiles of the major players in the global latanoprost market include Pfizer Inc., Thea Pharma Inc., Sun Pharmaceutical Industries Limited, Alcon, Taj Pharmaceuticals Limited, Viatris Inc., Apotex Inc., Wellona Pharma, Santen Pharmaceutical Co., Ltd., and Somerset Pharma LLC. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market Segments
By Type
Branded Drug
Generic Drug
By Indication
Open Angle Glaucoma
Ocular Hypertension
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Providers
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Pfizer Inc.
Thea Pharma Inc.
Sun Pharmaceutical Industries Limited
Alcon
Taj Pharmaceuticals Limited
Viatris Inc.
Apotex Inc.
Wellona Pharma
Santen Pharmaceutical Co., Ltd.
Somerset Pharma LLC
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- CHAPTER 4: LATANOPROST MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Branded Drug
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Generic Drug
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- CHAPTER 5: LATANOPROST MARKET, BY INDICATION
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
- 5.2. Open Angle Glaucoma
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Ocular Hypertension
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
- CHAPTER 6: LATANOPROST MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacies
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacies
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Providers
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
- CHAPTER 7: LATANOPROST MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Indication
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Latanoprost Market
- 7.2.6.1. Market Size and Forecast, By Type
- 7.2.6.2. Market Size and Forecast, By Indication
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Latanoprost Market
- 7.2.7.1. Market Size and Forecast, By Type
- 7.2.7.2. Market Size and Forecast, By Indication
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Latanoprost Market
- 7.2.8.1. Market Size and Forecast, By Type
- 7.2.8.2. Market Size and Forecast, By Indication
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Indication
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Latanoprost Market
- 7.3.6.1. Market Size and Forecast, By Type
- 7.3.6.2. Market Size and Forecast, By Indication
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. France Latanoprost Market
- 7.3.7.1. Market Size and Forecast, By Type
- 7.3.7.2. Market Size and Forecast, By Indication
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. UK Latanoprost Market
- 7.3.8.1. Market Size and Forecast, By Type
- 7.3.8.2. Market Size and Forecast, By Indication
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Italy Latanoprost Market
- 7.3.9.1. Market Size and Forecast, By Type
- 7.3.9.2. Market Size and Forecast, By Indication
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. Spain Latanoprost Market
- 7.3.10.1. Market Size and Forecast, By Type
- 7.3.10.2. Market Size and Forecast, By Indication
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest Of Europe Latanoprost Market
- 7.3.11.1. Market Size and Forecast, By Type
- 7.3.11.2. Market Size and Forecast, By Indication
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Indication
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Latanoprost Market
- 7.4.6.1. Market Size and Forecast, By Type
- 7.4.6.2. Market Size and Forecast, By Indication
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. China Latanoprost Market
- 7.4.7.1. Market Size and Forecast, By Type
- 7.4.7.2. Market Size and Forecast, By Indication
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Latanoprost Market
- 7.4.8.1. Market Size and Forecast, By Type
- 7.4.8.2. Market Size and Forecast, By Indication
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. Australia Latanoprost Market
- 7.4.9.1. Market Size and Forecast, By Type
- 7.4.9.2. Market Size and Forecast, By Indication
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. South Korea Latanoprost Market
- 7.4.10.1. Market Size and Forecast, By Type
- 7.4.10.2. Market Size and Forecast, By Indication
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Latanoprost Market
- 7.4.11.1. Market Size and Forecast, By Type
- 7.4.11.2. Market Size and Forecast, By Indication
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Indication
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Latanoprost Market
- 7.5.6.1. Market Size and Forecast, By Type
- 7.5.6.2. Market Size and Forecast, By Indication
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. Saudi Arabia Latanoprost Market
- 7.5.7.1. Market Size and Forecast, By Type
- 7.5.7.2. Market Size and Forecast, By Indication
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. South Africa Latanoprost Market
- 7.5.8.1. Market Size and Forecast, By Type
- 7.5.8.2. Market Size and Forecast, By Indication
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Latanoprost Market
- 7.5.9.1. Market Size and Forecast, By Type
- 7.5.9.2. Market Size and Forecast, By Indication
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping Of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Thea Pharma Inc.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. Sun Pharmaceutical Industries Limited
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Alcon
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Taj Pharmaceuticals Limited
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Viatris Inc.
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Apotex Inc.
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Wellona Pharma
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Santen Pharmaceutical Co., Ltd.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Somerset Pharma LLC
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
- LIST OF TABLES
- TABLE 1. GLOBAL LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 2. LATANOPROST MARKET FOR BRANDED DRUG, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 3. LATANOPROST MARKET FOR GENERIC DRUG, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 4. GLOBAL LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 5. LATANOPROST MARKET FOR OPEN ANGLE GLAUCOMA, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 6. LATANOPROST MARKET FOR OCULAR HYPERTENSION, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 7. GLOBAL LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 8. LATANOPROST MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 9. LATANOPROST MARKET FOR RETAIL PHARMACIES, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 10. LATANOPROST MARKET FOR ONLINE PROVIDERS, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 11. LATANOPROST MARKET, BY REGION, 2024 - 2033 ($BILLION)
- TABLE 12. NORTH AMERICA LATANOPROST MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 13. NORTH AMERICA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 14. NORTH AMERICA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 15. NORTH AMERICA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 16. U.S. LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 17. U.S. LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 18. U.S. LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 19. CANADA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 20. CANADA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 21. CANADA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 22. MEXICO LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 23. MEXICO LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 24. MEXICO LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 25. EUROPE LATANOPROST MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 26. EUROPE LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 27. EUROPE LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 28. EUROPE LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 29. GERMANY LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 30. GERMANY LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 31. GERMANY LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 32. FRANCE LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 33. FRANCE LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 34. FRANCE LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 35. UK LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 36. UK LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 37. UK LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 38. ITALY LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 39. ITALY LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 40. ITALY LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 41. SPAIN LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 42. SPAIN LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 43. SPAIN LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 44. REST OF EUROPE LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 45. REST OF EUROPE LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 46. REST OF EUROPE LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 47. ASIA-PACIFIC LATANOPROST MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 48. ASIA-PACIFIC LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 49. ASIA-PACIFIC LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 50. ASIA-PACIFIC LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 51. JAPAN LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 52. JAPAN LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 53. JAPAN LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 54. CHINA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 55. CHINA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 56. CHINA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 57. INDIA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 58. INDIA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 59. INDIA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 60. AUSTRALIA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 61. AUSTRALIA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 62. AUSTRALIA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 63. SOUTH KOREA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 64. SOUTH KOREA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 65. SOUTH KOREA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 66. REST OF ASIA-PACIFIC LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 67. REST OF ASIA-PACIFIC LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 68. REST OF ASIA-PACIFIC LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 69. LAMEA LATANOPROST MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
- TABLE 70. LAMEA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 71. LAMEA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 72. LAMEA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 73. BRAZIL LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 74. BRAZIL LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 75. BRAZIL LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 76. SAUDI ARABIA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 77. SAUDI ARABIA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 78. SAUDI ARABIA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 79. SOUTH AFRICA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 80. SOUTH AFRICA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 81. SOUTH AFRICA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 82. REST OF LAMEA LATANOPROST MARKET, BY TYPE, 2024 - 2033 ($BILLION)
- TABLE 83. REST OF LAMEA LATANOPROST MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
- TABLE 84. REST OF LAMEA LATANOPROST MARKET, BY DISTRIBUTION CHANNEL, 2024 - 2033 ($BILLION)
- TABLE 85. PFIZER INC.: KEY EXECUTIVES
- TABLE 86. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 87. PFIZER INC.: OPERATING SEGMENTS
- TABLE 88. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 89. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 90. THEA PHARMA INC.: KEY EXECUTIVES
- TABLE 91. THEA PHARMA INC.: COMPANY SNAPSHOT
- TABLE 92. THEA PHARMA INC.: OPERATING SEGMENTS
- TABLE 93. THEA PHARMA INC.: PRODUCT PORTFOLIO
- TABLE 94. THEA PHARMA INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 95. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 96. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 97. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS
- TABLE 98. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- TABLE 99. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 100. ALCON: KEY EXECUTIVES
- TABLE 101. ALCON: COMPANY SNAPSHOT
- TABLE 102. ALCON: OPERATING SEGMENTS
- TABLE 103. ALCON: PRODUCT PORTFOLIO
- TABLE 104. ALCON: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 105. TAJ PHARMACEUTICALS LIMITED: KEY EXECUTIVES
- TABLE 106. TAJ PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
- TABLE 107. TAJ PHARMACEUTICALS LIMITED: OPERATING SEGMENTS
- TABLE 108. TAJ PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
- TABLE 109. TAJ PHARMACEUTICALS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 110. VIATRIS INC.: KEY EXECUTIVES
- TABLE 111. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 112. VIATRIS INC.: OPERATING SEGMENTS
- TABLE 113. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 114. VIATRIS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 115. APOTEX INC.: KEY EXECUTIVES
- TABLE 116. APOTEX INC.: COMPANY SNAPSHOT
- TABLE 117. APOTEX INC.: OPERATING SEGMENTS
- TABLE 118. APOTEX INC.: PRODUCT PORTFOLIO
- TABLE 119. APOTEX INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 120. WELLONA PHARMA: KEY EXECUTIVES
- TABLE 121. WELLONA PHARMA: COMPANY SNAPSHOT
- TABLE 122. WELLONA PHARMA: OPERATING SEGMENTS
- TABLE 123. WELLONA PHARMA: PRODUCT PORTFOLIO
- TABLE 124. WELLONA PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 125. SANTEN PHARMACEUTICAL CO., LTD. : KEY EXECUTIVES
- TABLE 126. SANTEN PHARMACEUTICAL CO., LTD. : COMPANY SNAPSHOT
- TABLE 127. SANTEN PHARMACEUTICAL CO., LTD. : OPERATING SEGMENTS
- TABLE 128. SANTEN PHARMACEUTICAL CO., LTD. : PRODUCT PORTFOLIO
- TABLE 129. SANTEN PHARMACEUTICAL CO., LTD. : KEY STRATEGIC MOVES AND DEVELOPMENTS
- TABLE 130. SOMERSET PHARMA LLC : KEY EXECUTIVES
- TABLE 131. SOMERSET PHARMA LLC : COMPANY SNAPSHOT
- TABLE 132. SOMERSET PHARMA LLC : OPERATING SEGMENTS
- TABLE 133. SOMERSET PHARMA LLC : PRODUCT PORTFOLIO
- TABLE 134. SOMERSET PHARMA LLC : KEY STRATEGIC MOVES AND DEVELOPMENTS
- LIST OF FIGURES
- FIGURE 1. GLOBAL LATANOPROST MARKET, 2024 - 2033
- FIGURE 2. SEGMENTATION OF LATANOPROST MARKET, 2024 - 2033
- FIGURE 3. TOP INVESTMENT POCKET IN LATANOPROST MARKET
- FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
- FIGURE 7. LOW THREAT OF SUBSTITUTION
- FIGURE 8. HIGH COMPETITIVE RIVALRY
- FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLATANOPROST MARKET
- FIGURE 10. GLOBAL LATANOPROST MARKET SEGMENTATION, BY TYPE
- FIGURE 11. LATANOPROST MARKET FOR BRANDED DRUG, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 12. LATANOPROST MARKET FOR GENERIC DRUG, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 13. GLOBAL LATANOPROST MARKET SEGMENTATION, BY INDICATION
- FIGURE 14. LATANOPROST MARKET FOR OPEN ANGLE GLAUCOMA, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 15. LATANOPROST MARKET FOR OCULAR HYPERTENSION, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 16. GLOBAL LATANOPROST MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
- FIGURE 17. LATANOPROST MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 18. LATANOPROST MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 19. LATANOPROST MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2024 - 2033 ($BILLION)
- FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
- FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
- FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
- FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 24. COMPETITIVE DASHBOARD
- FIGURE 25. COMPETITIVE HEATMAP: LATANOPROST MARKET
- FIGURE 26. TOP PLAYER POSITIONING, 2023
- FIGURE 27. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 28. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 29. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 30. THEA PHARMA INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 31. THEA PHARMA INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 32. THEA PHARMA INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 33. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2021-2023 ($BILLION)
- FIGURE 34. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 35. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 36. ALCON: NET SALES, 2021-2023 ($BILLION)
- FIGURE 37. ALCON: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 38. ALCON: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 39. TAJ PHARMACEUTICALS LIMITED: NET SALES, 2021-2023 ($BILLION)
- FIGURE 40. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 41. TAJ PHARMACEUTICALS LIMITED: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 42. VIATRIS INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 43. VIATRIS INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 44. VIATRIS INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 45. APOTEX INC.: NET SALES, 2021-2023 ($BILLION)
- FIGURE 46. APOTEX INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 47. APOTEX INC.: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 48. WELLONA PHARMA: NET SALES, 2021-2023 ($BILLION)
- FIGURE 49. WELLONA PHARMA: REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 50. WELLONA PHARMA: REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 51. SANTEN PHARMACEUTICAL CO., LTD. : NET SALES, 2021-2023 ($BILLION)
- FIGURE 52. SANTEN PHARMACEUTICAL CO., LTD. : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 53. SANTEN PHARMACEUTICAL CO., LTD. : REVENUE SHARE, BY REGION, 2023 (%)
- FIGURE 54. SOMERSET PHARMA LLC : NET SALES, 2021-2023 ($BILLION)
- FIGURE 55. SOMERSET PHARMA LLC : REVENUE SHARE, BY SEGMENT, 2023 (%)
- FIGURE 56. SOMERSET PHARMA LLC : REVENUE SHARE, BY REGION, 2023 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook